More recently, we found that Eritoran inhibited tumor growth through immunomodulation and vascular normalization, and that the carboxyl-terminal sequences of mouse S100A8 were necessary for binding to the mouse TLR4/MD-2 complex using a binding assay and CyClus docking simulation [8]. This evidence concerns the gene TLR4 and neoplasm.